原標(biāo)題：黃花蒿舌下免疫療法治療季節(jié)性過敏性鼻炎：一項(xiàng)隨機(jī)對照試驗(yàn)
背景：黃花蒿是中國北方季節(jié)過敏性鼻炎（SAR）的一種重要秋季花粉過敏原。到目前為止，還沒有一項(xiàng)研究調(diào)查過黃花蒿過敏原免疫治療的情況。本研究旨在探討黃花蒿舌下免疫療法（SLIT）的療效和機(jī)制。
方法：這是一項(xiàng)隨機(jī)、雙盲、安慰劑對照的III期臨床試驗(yàn)，共有71名SAR患者，隨機(jī)分為兩組，分別用黃花蒿提取物（n=47）或安慰劑（n=24）舌下免疫治療32周。在基線（上一年的峰值花粉期（PPP）），SLIT開始，SLIT期間的第1個PPP，SLIT結(jié)束和隨訪期間第2個PPP這幾個時段評估鼻總癥狀評分（TNSS；主要臨床終點(diǎn)）。在SLIT開始和之后收集血液樣本和鼻分泌物，以評估T細(xì)胞和炎性介質(zhì)。根據(jù)報告的不良事件（AEs）評估安全性。
結(jié)果：在第一個PPP（P <.001）時，黃花蒿SLIT顯著降低TNSS至基線水平（從9.45±1.68降低至6.16±2.27），高于安慰劑（從9.29±2.09降低至9.05±2.40），并且上述改善一直持續(xù)到第二個 PPP。另外，季前性黃花蒿SLIT治療16周能夠顯著降低血液中的Th2細(xì)胞和增加nTreg和Tr1細(xì)胞；與預(yù)處理相比，治療后第16周和32周鼻分泌物中的半胱氨酸蛋白酶抑制劑1（CST1）升高?？偟膩碚f，黃花蒿SLIT治療后，17/47名患者出現(xiàn)了輕度局部AEs，2名患者出現(xiàn)了輕度全身性AEs。
結(jié)論：黃花蒿SLIT是一種安全有效的黃花蒿SAR治療方法。


延伸閱讀
Allergy
Artemisia annua-sublingual immunotherapy for seasonal allergic rhinitis: 
A randomized controlled trial
DOI: 10.1111/all.14218
Abstract:
Background: Artemisia annua is an important autumnal pollen allergen for seasonal allergic rhinitis (SAR) in northern China. To date, no study has investigated allergen immunotherapy with A annua. We aimed to investigate the efficacy and mechanisms underlying A annua-sublingual immunotherapy (SLIT).
Methods: This was a randomized, double-blind, placebo-controlled phase III clinical trial involving 71 SAR patients, randomized to SLIT with A annua extract (n = 47) or placebo (n = 24) for 32 weeks. Total nasal symptom score (TNSS; primary clinical end point) was evaluated at baseline (peak pollen phase (PPP) in the previous year), initiation of A annua-SLIT, 1st PPP during SLIT, end of SLIT and 2nd PPP during follow-up. Blood samples and nasal secretions were collected at beginning and after SLIT for assessment of T cells and inflammatory mediators. Safety was assessed according to adverse events (AEs) reported.
Results: Artemisia annua-SLIT significantly reduced TNSS to a greater level from baseline (from 9.45 ± 1.68 to 6.16 ± 2.27) than placebo (from 9.29 ± 2.09 to 9.05 ± 2.40) at the 1st PPP (P < .001) and sustained the improvement in symptoms throughout to the 2nd PPP. Preseasonal A annua-SLIT for 16 weeks significantly decreased Th2 cells, increased nTreg and Tr1 cells in blood; and increased cystatin 1 (CST1) in nasal secretion after 16 and 32 weeks compared with pretreatment. Overall, 17/47 patients experienced mild local AEs and 2 patients mild systemic AEs, after A annua-SLIT.
Conclusion: Artemisia annua-SLIT is an efficacious and safe treatment in patients with A annua SAR.
First Author:
Hongfei Lou,  Chengshuo Wang
Correspondence:
Chengshuo Wang, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No.1, Dongjiaominxiang, DongCheng District, Beijing 100730, China.
All Authors:
Hongfei Lou, Yanran Huang,Yuhui Ouyang,Yuan Zhang, Lin Xi, Xiaohan Chu, Yang Wang, Chengshuo Wang, Luo Zhang
2020-08-19 Article 
　　創(chuàng)建過敏性疾病的科研、科普知識交流平臺，為過敏患者提供專業(yè)診斷、治療、預(yù)防的共享平臺。